文献速递前列腺癌

用于前列腺癌早期检测的液体生物标志物及非裔美国男性使用现有数据的总结

Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-03-04

本文以临床实用为导向综述了当前可用的前列腺癌液体生物标志物检测(包括游离PSA百分比、前列腺健康指数、PCA3、ExoDx前列腺检测、SelectMDx、4Kscore和Mi-Prostate Score),重点评价其在非裔血统男性中的表现,并总结了针对该人群的现有研究证据。结论认为液体生物标志物有助于前列腺穿刺前的风险分层,但使用应个体化,后续研究应优先评估非裔血统男性中的数据。

要点

  • 多种液体生物标志物可用于前列腺穿刺前风险分层,但需结合充分证据个体化使用。
  • 非裔血统是前列腺癌既定危险因素,评估液体生物标志物时须特别考虑。
  • 现有针对非裔血统男性的液体生物标志物证据有限,后续研究应优先评估该人群。

核心结论

  • 液体生物标志物可作为前列腺穿刺前风险分层的有用工具。
  • 此类检测的使用应基于对支持证据的充分了解和患者与医师的目标进行个体化。
  • 后续研究应优先评估非裔血统男性中此类生物标志物的表现。

研究设计与样本

  • 综述,回顾当前可用的液体生物标志物检测的发现与验证研究,并以临床实用为导向进行评价。
  • 对专门针对非裔血统男性的证据进行了文献综述并总结现有研究。

主要发现

  • 讨论了游离PSA百分比、前列腺健康指数、Progensa® PCA3、ExoDx®前列腺检测、SelectMDx®、4Kscore®检测和Mi-Prostate Score各自的优势与局限性。
  • 总结了上述检测的重要研究及针对非裔血统男性的现有研究证据。

临床怎么用

  • 液体生物标志物可用于辅助前列腺穿刺前风险分层,但使用应个体化。
  • 选择检测时应充分了解支持证据,并结合患者与医师的目标。

局限性

  • 原文指出后续研究应优先评估非裔血统男性中的此类生物标志物,提示该人群现有证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several liquid biomarker tests have been developed to account for the limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African ancestry is an established risk factor for prostate cancer (PCa) and must be particularly considered when evaluating patients with liquid biomarkers. While multiple tests have been developed over decades of exploration, recent advances can help patients and physicians incorporate data into a broader clinical context. METHODS: We sought to review currently available liquid biomarker tests in a practical, clinically directed fashion with particular focus on performance in men with African ancestry. We reviewed discovery and validation studies and highlight important considerations for each test. RESULTS: We discuss the advantages and limitations of percent free PSA, Prostate Health Index, Progensa® PCA3, ExoDx® Prostate Test, SelectMDx®, 4Kscore® Test, and Mi-Prostate Score and summarize salient studies on their use. A literature review of evidence specifically for men with African ancestry was conducted and available studies were summarized. CONCLUSIONS: Liquid biomarkers can be useful tools for aiding in risk stratification prior to prostate biopsy. Use of such tests should be individualized based on a thorough knowledge of supporting evidence and the goals of the patient and physician. Further study should prioritize evaluation of such biomarkers in men with African ancestry.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Henning GM, Andriole GL, Kim EH, et al. Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men. Prostate Cancer Prostatic Dis. 2022. PMID: 35246608. doi:10.1038/s41391-022-00507-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。